로딩 중…
StockDiggingStockDigging

Qiagen N.V.

QGEN· NYSE
NLNL
$44.39+3.47%
2026-09-17

Financials

Valuation Metrics

Qiagen N.V.'s Market Cap is $9.16B. At end of 2025 it was $9.84B. Ranked #977 of 3,121 in US market (top 31%), #661 of 1,658 on NYSE (top 40%), #73 of 205 in Health Care Equipment & Services (top 36%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$9.16B
Revenue$2.10B
Net Income$409M
Total Assets$5.89B
Net Assets$3.36B
Employees5,500
Value
P/E22.37x
P/B2.73x
PEG2.32x
P/S4.36x
EV/EBITDA13.63x
FCF Yield4.89%
Profitability
ROE12.19%
ROA6.95%
Op. Margin25.33%
Revenue Growth2.96%
Earnings Growth9.62%
Financial Health
Debt Ratio75.39%
Total Debt$1.64B
FCF$448M
Cash$769M
Current Ratio2.85x
Net Debt/EBITDA1.19x
Dividend
Div. Yield0.59%
Performance
1Y Return-2.27%
1M Return4.89%
From 52W High-23.23%
1Y MDD-41.38%
Trading
Volume1,645,430 shares
Trading Value$73M
Per Share
EPS$1.98
BPS$16.28

Company Info

CEO Thierry Bernard
Employees 5,500
HQ Venlo, NL

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.